Cargando…

Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats.

The possible protective effect of an agonist of luteinising hormone-releasing hormone (LH-RH) against the ovarian damage caused by cyclophosphamide was investigated in rats. D-Trp6-LH-RH microcapsules were injected once a month for 3 months, in a dose calculated to release 25 micrograms day-1. Contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bokser, L., Szende, B., Schally, A. V.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1990
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971695/ https://www.ncbi.nlm.nih.gov/pubmed/2142603

Ejemplares similares

Hypothalamic effects of progesterone on regulation of the pulsatile and surge release of luteinising hormone in female rats
por: He, Wen, et al.
Publicado: (2017)

Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
por: Plowman, P. N., et al.
Publicado: (1986)

Adjuvant gonadotropin releasing hormone analog in gonadotoxic chemotherapy for preservation of fertility
por: Kumar, K. V. S. Hari, et al.
Publicado: (2013)

Use of luteinising hormone-releasing hormone agonist (leuprorelin) in advanced post-menopausal breast cancer: clinical and endocrine effects.
por: Crighton, I. L., et al.
Publicado: (1989)

Unravelling the Protective Effects of Emodin Against Cyclophosphamide Induced Gonadotoxicity in Male Wistar Rats
por: Wang, Yinhua, et al.
Publicado: (2021)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Measuring luteinising hormone pulsatility with a robotic aptamer-enabled electrochemical reader
por: Liang, Shaolin, et al.
Publicado: (2019)

A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol
por: Langley, Ruth E., et al.
Publicado: (2016)

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers
por: Szepeshazi, K, et al.
Publicado: (2000)

A review of luteinising hormone and human chorionic gonadotropin when used in assisted reproductive technology
por: Ezcurra, Diego, et al.
Publicado: (2014)

Growth Hormone-Releasing Hormone in Diabetes
por: Fridlyand, Leonid E., et al.
Publicado: (2016)

Luteinising hormone-based protocol versus traditional flexible gonadotropin-releasing hormone antagonist protocol in women with normal ovarian response: study protocol for a non-inferiority trial
por: Lv, Ya-su, et al.
Publicado: (2021)

Circulating levels of testosterone, 17 beta-oestradiol, luteinising hormone and prolactin in postmenopausal breast cancer patients.
por: Secreto, G., et al.
Publicado: (1983)

Involvement of the unfolded protein response in the protective effects of growth hormone releasing hormone antagonists in the lungs
por: Akhter, Mohammad S., et al.
Publicado: (2020)

Gonadotropin-releasing hormone antagonist versus progestin for the prevention of premature luteinising hormone surges in poor responders undergoing in vitro fertilisation treatment: study protocol for a randomised controlled trial
por: Wang, Yun, et al.
Publicado: (2018)

Growth hormone releasing hormone induces the expression of nitric oxide synthase
por: Barabutis, Nektarios, et al.
Publicado: (2011)

Field study assessing the performance of a patient-side blood test to determine neuter status in female cats based on detection of luteinising hormone
por: Morrow, Lisa D, et al.
Publicado: (2018)

Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis
por: Wang, Chuan, et al.
Publicado: (2013)

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09)
por: Langley, Ruth E, et al.
Publicado: (2013)

FRI379 The Gonadotoxic Effects Of Cyclophosphamide And Busulfan On Ovaries In CD-1 Mouse Model
por: Thonen, Macy, et al.
Publicado: (2023)

Protective effects of growth hormone-releasing hormone analogs in DSS-induced colitis in mice
por: Recinella, Lucia, et al.
Publicado: (2021)

Growth Hormone-Releasing Hormone in Lung Physiology and Pulmonary Disease
por: Zhang, Chongxu, et al.
Publicado: (2020)

Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1
por: Cui, Tengjiao, et al.
Publicado: (2018)

Protective effects of agonists of growth hormone-releasing hormone (GHRH) in early experimental diabetic retinopathy
por: Thounaojam, Menaka C., et al.
Publicado: (2017)

Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines
por: Barabutis, N, et al.
Publicado: (2008)

Protective effect of gonadotropin-releasing hormone analog on the ovarian reserve in rats receiving cyclophosphamide treatment
por: Gui, Ting, et al.
Publicado: (2015)

Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction
por: Czikora, Istvan, et al.
Publicado: (2014)

Paradoxical risk of reduced fertility after exposure of prepubertal mice to vincristine or cyclophosphamide at low gonadotoxic doses in humans
por: Delessard, Marion, et al.
Publicado: (2020)

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.
por: Jungwirth, A., et al.
Publicado: (1997)

Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study
por: D'Avila, Ângela Marcon, et al.
Publicado: (2017)

Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway
por: Guo, Jian, et al.
Publicado: (2010)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

Tumorigenic transformation of human prostatic epithelial cell line RWPE‐1 by growth hormone‐releasing hormone (GHRH)
por: Muñoz‐Moreno, Laura, et al.
Publicado: (2022)

Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin
por: Zhang, Chongxu, et al.
Publicado: (2019)

Effect of insulin-like growth factor system on luteinising angiogenesis
por: Nwachukwu, Chinwe U, et al.
Publicado: (2023)

Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers
por: Perez, Roberto, et al.
Publicado: (2012)

Growth hormone-releasing hormone agonist attenuates vascular calcification in diabetic db/db mice
por: Ren, Hao-Lin, et al.
Publicado: (2023)

Agonist of growth hormone-releasing hormone improves the disease features of spinal muscular atrophy mice
por: Boido, Marina, et al.
Publicado: (2023)

Antinflammatory, antioxidant, and behavioral effects induced by administration of growth hormone-releasing hormone analogs in mice
por: Recinella, Lucia, et al.
Publicado: (2020)

SAT-603 Growth Hormone-Releasing Hormone (GHRH) Antagonists Stimulate Feeding in Mice
por: Leone, Sheila, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8mdkncou9l0dj5covi0vtiev52